13F HOLDINGS REPORT
Decheng Capital Management III (Cayman), LLC
Quarter ended Q1 2023 · Filed February 9, 2023 · Accession 0001104659-23-017522
Total Value
$267.2M
Positions
26
Other Managers
0
Confidential Omitted
No
Holdings (26)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Alpine Immune Sciences, Inc. | 010392595 | 6,708,288 | $49.3M | 18.45% |
| 2 | Zentalis Pharmaceuticals Inc. | ZNTL | 1,824,583 | $36.7M | 13.75% |
| 3 | Prometheus Biosciences, Inc. | 74349U108 | 250,000 | $27.5M | 10.29% |
| 4 | Cue Health Inc. | 229790100 | 8,980,909 | $18.6M | 6.96% |
| 5 | Arcus BioSciences, Inc. | RCUS | 869,790 | $18.0M | 6.73% |
| 6 | Illumnia, Inc. | ILMN | 80,859 | $16.3M | 6.12% |
| 7 | Albireo Pharma, Inc. | 01345P106 | 623,342 | $13.5M | 5.04% |
| 8 | 10x Genomics, Inc. | TXG | 359,554 | $13.1M | 4.90% |
| 9 | Pacific Biosciences of California, Inc. | 69404D108 | 1,463,872 | $12.0M | 4.48% |
| 10 | BeyondSpring Inc. | BYSI | 4,958,143 | $9.3M | 3.49% |
| 11 | Horizon Therapeutics PLC | G46188101 | 78,900 | $9.0M | 3.36% |
| 12 | Terns Pharmaceuticals, Inc. | TERN | 714,285 | $7.3M | 2.72% |
| 13 | Aadi Bioscience, Inc. | WHWK | 526,329 | $6.8M | 2.53% |
| 14 | Mersana Therapeutics, Inc. | 59045L106 | 904,268 | $5.3M | 1.98% |
| 15 | Adicet Bio, Inc. | ACET | 580,000 | $5.2M | 1.94% |
| 16 | Equillium Inc. | EQ | 4,447,308 | $4.9M | 1.83% |
| 17 | Aura Biosciences, Inc. | AURA | 293,333 | $3.1M | 1.15% |
| 18 | Seagen Inc. | SE | 23,014 | $3.0M | 1.11% |
| 19 | Argenx SE | ARGX | 5,529 | $2.1M | 0.78% |
| 20 | AtriCure Inc. | ATRC | 46,259 | $2.1M | 0.77% |
| 21 | Apexigen, Inc. | 03759B102 | 1,894,551 | $1.3M | 0.48% |
| 22 | GeneDx Holdings Corp. | 81663L101 | 3,418,929 | $902,597 | 0.34% |
| 23 | Scynexis Inc. | SCYX | 555,555 | $866,666 | 0.32% |
| 24 | Nautilus Biotechnology, Inc. | NAUT | 300,000 | $540,000 | 0.20% |
| 25 | Owlet, Inc. | OWLTW | 898,400 | $502,295 | 0.19% |
| 26 | NeuBase Therapeutics, Inc. | 64132K102 | 1,000,000 | $190,200 | 0.07% |